Clinical trial
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
NCT00098345 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00098345 |
|---|---|
| Title | Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer |
| Official title | An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma. |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thyroid Cancer |
| Intervention type | Drug |
| Interventions | ZD6474 (vandetanib) |
| Enrollment | 40 |
| Start date | Nov 1, 2004 |
| Primary completion | Feb 1, 2008 |
| Completion | Apr 19, 2017 |
| First posted | Dec 8, 2004 |
| Last update posted | May 7, 2018 |
| Countries | France, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: